Welcome to our dedicated page for AINOS news (Ticker: AIMDW), a resource for investors and traders seeking the latest updates and insights on AINOS stock.
Ainos, Inc. (AIMD, AIMDW) generates news around its efforts to digitize smell for artificial intelligence and to build a SmellTech platform that combines hardware, software, and data. Company updates frequently highlight progress with its AI Nose electronic nose system, the Smell ID data format, and the Smell Language Model (SLM), as well as developments in its biotech program centered on the oral interferon candidate VELDONA.
News coverage for Ainos often focuses on industrial and technology partnerships. The company has announced collaborations with semiconductor solution providers, industrial computing and edge AI companies, and automation and robotics firms to integrate AI Nose into manufacturing and industrial environments. These stories describe how AI Nose is being deployed in semiconductor fabrication, smart factories, and robotic systems to provide real-time environmental sensing, predictive analytics, and alerts.
Investors can also find corporate and capital markets updates in Ainos-related news, including information on its Global Industry Classification Standard reclassification into the technology sector, At The Market Offering Agreement activity, and reverse stock split of its common stock. Earnings releases and business updates provide context on commercialization milestones, pilot programs in senior care and robotics, and the expansion of the company’s SmellTech-as-a-Service model.
For those following AIMDW, the warrant listing associated with Ainos common stock, the news stream offers insight into the company’s strategic direction, platform evolution, and partnerships. Regularly reviewing these articles can help readers understand how Ainos is positioning AI Nose and ScentAI within semiconductors, edge AI, healthcare, and robotics, and how these initiatives relate to its broader dual-platform AI and biotech strategy.
Ainos (NASDAQ:AIMD) is moving from validation to execution with visible 2026 deployment momentum for its AI Nose Smell AI platform. Key metrics: 2025 revenue +499% YoY, 82.9% gross margin, ~99% revenue tied to AI Nose, a $2.1M three-year subscription for ~1,400 systems targeted Q2 2026, plus ~200 validation units and 600 committed systems, supported by $350k customer deposits and ~$2.82M in new financing.
Ainos (NASDAQ:AIMD) reported 2025 results showing ~499% revenue growth and a swing to positive gross margin of 82.9%. The company secured a New Taiwan Dollar 90 million financing (~USD $2.82M) and announced early 2026 semiconductor deployments: ~200 front-end systems and 1,400 systems under a three-year $2.1M program with deposits received and a roadmap to 20,000 systems.
Management emphasized scaled AI Nose commercial deployments, recurring Smell ID and Smell Language Model monetization, and disciplined capital allocation entering 2026.
Ainos (NASDAQ:AIMD) is advancing commercial deployment of its AI Nose digital olfaction platform, highlighted in The Wall Street Journal piece on emerging "Smell AI." The company has a signed deployment of 1,400 systems in backend semiconductor environments and is targeting up to 20,000 systems as a longer-term roadmap. Ainos is also pursuing ~200 systems for front-end wafer fabs and early integrations with robotic and quadruped inspection platforms. The company emphasizes multi-year growth potential, recurring revenue models, and development of Smell Tech data infrastructure.
Ainos (NASDAQ:AIMD) is scaling AI Nose deployments across semiconductor manufacturing, with front-end and back-end initiatives driving recurring subscription revenue.
Key metrics: ~200 systems planned for front-end wafer fabs in 1Q26, 1,400 Phase 1 systems for ASE completing in 2Q26, generating ≈$2.1M over three years and a potential $10M annual subscription run‑rate if a 20,000‑system roadmap executes.
Ainos (NASDAQ:AIMD) announced continued validation of its AI Nose platform in front-end wafer fabs with ~200 targeted deployments planned in Q1 2026 for technical validation.
It is executing Phase 1 of a 1,400-system back-end deployment worth approximately $2.1 million under a three-year subscription, targeting completion in Q2 2026. The broader roadmap contemplates up to 20,000 systems, which the company says could approach $10 million in annual subscription value, all subject to technical validation and contractual conversion. Management says milestones and subscription activation plans remain unchanged despite market volatility.
Ainos (NASDAQ:AIMD) outlined a phased deployment plan for up to 20,000 AI Nose systems, anchored by a confirmed initial order of 1,400 systems.
The initial order activates recurring subscription revenue under a three-year service structure totaling approximately $2.1 million, and the roadmap states potential annual order values approaching $10 million if fully executed, subject to staged technical validation and formal contractual conversion.
Validation testing is underway in advanced semiconductor front-end fabrication environments to support commercial integration and multi-site industrial scaling.
Ainos (NASDAQ:AIMD) activated a phased industrial deployment roadmap to install up to 20,000 AI Nose units in semiconductor production environments under a strategic framework with ASE Technology Holding.
Phase one includes a confirmed order of 1,400 units under a three-year subscription (~$2.1M), $350,000 in customer deposits, and a target completion by end of Q2 2026. Later phases (5,000 and up to 15,000 units) depend on milestone validation and contractual progression.
Ainos (NASDAQ:AIMD) reported statistically significant interim efficacy from its open-label VELDONA trial in feline chronic gingivostomatitis (FCGS). In six treated cats, mean oral inflammation improved ~38% at Week 6 and ~45% at Week 14, with 66.7% of subjects achieving ≥30% improvement.
Safety signals were absent: liver and renal labs remained stable and VELDONA was well tolerated. Enrollment continues to 12 subjects to assess dose response and durability.
Ainos (NASDAQ:AIMD) began live AI Nose deployments in semiconductor manufacturing after receiving an initial $2.1 million order from a back-end packaging and testing customer. Preparations in the second half of 2025 enabled on-site rollouts that started in January 2026.
Back-end deployments are now operating in live environments generating scent data, while front-end semiconductor pilots advance to broaden use cases and strengthen Ainos' Smell Language Model (SLM).
Ainos (NASDAQ:AIMD) announced a strategic partnership with Mirle to integrate its AI Nose SmellTech into Mirle's mobile and quadruped robotic platforms, extending deployments from commercial buildings into industrial environments such as semiconductor fabs and advanced manufacturing.
The collaboration aims to add chemical sensing to vision and audio, improve early detection of gas leaks and VOCs, and accelerate real-world data collection to scale the Smell ID library and platform capabilities.